Trinity College Dublin

Skip to main content.

Top Level TCD Links


New treatment regiments for the treatment of this disease are underway in association with autologous transplantation. These new treatments include thalidomide, thalidomide analogues and proteasome inhibitors. Our research focuses on molecular epidemiology of myeloma and investigation of novel treatment strategies.


Tewari P, Ryan AW, Hayden PJ, Catherwood M, Drain S, Staines A, Grant T, Nieters A, Becker N, de Sanjose S, Foretova L, Maynardie M, Cocco P, Boffetta P, Brennan P, Chanock S, Lawler M, Browne PV. Genetic variation at the 8q24 locus confers risk to multiple myeloma. Br J Haematol. 2012; 156(1):133-6.

Maginn EN, Browne PV, Hayden P, Vandenberghe E, MacDonagh B, Evans P, Goodyer M, Tewari P, Campiani G, Butini S, Williams DC, Zisterer DM, Lawler MP, McElligott AM. PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cells. Br J Cancer. 2011; 104(2):281-9.

Tewari P, Kenny E, Staines A, Chanock S, Browne P, Lawler M. Genetic variants in XRRC5 may predict development of venous thrombotic events in myeloma patients on thalidomide. Blood. 2009; 113(22):5691-2.

Principal Investigators

Principal Investigator Email Telephone
Dr Paul Browne +353 1 416 2166
Dr P. Hayden  

Dr Tony McElligott +353 1 896 3276

Back to list of Research Projects

Last updated 21 September 2016 School Web Administrator (Email).